HLA-A and cancer: Tebentafusp is one of the most recent innovations for metastatic UM, which is an immune-mobilizing monoclonal T cell receptor (TCR) against cancer (ImmTAC; immune-mobilizing monoclonal TCRs against cancer) targeting HLA-A*0201.gp100280-288 and CD3 [10].